INTRODUCTION
The use of pay for performance incentive schemes as a quality improvement tool is increasing, particularly in North America and the United Kingdom. [1] [2] [3] Such schemes aim to improve the quality of health care for all patients so that care meets established standards. Pay for performance, therefore, provides an important opportunity to address disparities in chronic disease management between ethnic and socioeconomic groups. 4, 5 Equally, it has been argued that pay for performance programmes have the potential to worsen health care disparities. 6 Despite this few pay for performance schemes have been subject to rigorous evaluation and their impact on ethnic disparities in the quality of chronic disease management remains unclear. 7, 8 A new family practitioner contract, introduced in 2004 by the United Kingdom's National Health Service, designates that around 25% of a family practitioner's income would be determined by performance against targets in a new Quality and Outcomes Framework. The framework contains a large number of evidence-based quality indicators that were agreed between the government and family practitioners. The introduction of the new contract in the UK offers the opportunity to examine the impact of pay for performance in a healthcare system that offers universal access to health care. Statistics from the first year (2004-05) of the family practitioner contract suggest that most practices reached many of the higher Quality and Outcome Framework targets for Coronary Heart Disease (CHD). 9, 10 However, Quality and Outcomes Framework data, published by the Department of Health in England, are aggregated to practice level and do not permit examination of the impact of performance incentives on variations in care around key demographic variables such as age, gender and ethnicity.
Ethnic group disparities in cardiovascular disease prevalence and related health outcomes have been well documented in North America and the United Kingdom (UK). [11] [12] [13] South Asians (people with ancestry in countries from the Indian subcontinent) comprise more than one-fifth of the global population and have particularly high rates of CHD related morbidity and mortality. In the UK, mortality from CHD is up to 40% higher in south Asians but appears lower in black African and Caribbean groups when compared to white groups.
These disparities may result from inequitable access to high quality care. There is considerable evidence highlighting inequity in access to cardiovascular care between ethnic groups in the United States. 15, 16 Fewer studies have been conducted in the UK and in particular there is little research on the quality and appropriateness of CHD management amongst black groups. In a prospective cohort study of patients deemed appropriate for coronary artery bypass grafting attending a tertiary cardiac centre in London, south Asian patients were found to be less likely than white patients to receive surgery. 17 However, in a study of over 10,000 civil servants based in London, south Asian ethnicity was not associated with lower use of cardiac procedures or drugs, independently of clinical need. 18 In this paper, we test the hypothesis that pay for performance programmes reduce disparities in CHD management and outcomes within a multiethnic population. 
METHODS

Pay for Performance in UK Primary
Study Setting
In England, the provision of primary care services is the responsibility of primary care trusts. There are approximately 150 primary care trusts in the country which typically cover a population of 300,000 to 400,000 people. 
Identification of Patients with Coronary Heart Disease
The methods we used to develop our disease register for CHD in Wandsworth have been described previously. 20 In brief, all practices in the study area were asked to participate and all patients with CHD were identified by searching for diagnoses of CHD or a repeat prescription for nitrates. Patients with management codes for a positive angiography test or for cardiac bypass surgery and coronary angioplasty were also identified. Medical records were then checked to confirm the diagnosis of CHD.
Study Variables
We As the overall percentage of missing data was low (3.1%), all analyses were restricted to patients with complete information, with missing data having little bearing on our conclusions. Overall, the four practices that did not participate in the study accounted for less than 6% of the registered population in the study area. Non-participating practices were smaller (3 of 4 had fewer than 3000 patients) and located in more deprived areas than participating practices. 
PROCESS OF CARE MEASURES
DISCUSSION Principal Findings
Significantly more patients achieved established quality indicators for CHD after the implementation of a major pay for performance programme in UK primary care. The distribution of improvements between ethnic groups was such that some of the existing disparities in prescribing and intermediate clinical outcomes were attenuated. For example, worse blood pressure control in black patients relative to whites evident in 2003 was attenuated in 2005. However, black patients remained significantly less likely to be prescribed a statin after implementation of the UK pay for performance scheme.
Comparison with Previous Research
Few studies have examined the impact of pay for performance incentives on ethnic disparities in chronic disease management and outcomes. 7, 8 Prescribing of secondary prevention drugs increased significantly after the introduction of the new contract but levels were broadly similar between ethnic groups in both 2003 and 2005; the only exception being lower prescribing of statins in black patients in both years. These findings are in keeping with previous UK studies, including Whitehall II 18 and 
Strengths and Limitations
We are cautious in attributing changes seen to pay for performance incentives, given the limitations of our study design; an observational study with two time points and no control group. Because the new contract for family practitioners in the UK was introduced nationally, evaluation of these incentives using a more rigorous study design, such as a randomised controlled trial, was not feasible. Recent observational studies indicate that the management of CHD in UK primary care was improving before the introduction of the contract. 30 Hence, changes reported here may, in part, reflect a general trend toward higher quality care unrelated to the implementation of pay for performance incentives. In a recent study, Campbell et al. 31 found pay for performance was associated with a significant increase in the overall rate of improvement for asthma and diabetes management but not for coronary heart disease management in 42 volunteer family practices in six geographical areas in England. Our population-based study covered virtually all of the registered population in one area of south London. Hence our findings provide a comprehensive picture of the care provided in this diverse, inner city location. We employed an established and validated search strategy to identify known CHD cases. Our findings may represent a more complete picture of CHD management than that derived from national contract data, which determine individual practice income and may exclude a considerable proportion of patients who have been exception reported by practices for poor treatment compliance. 10 The high percentage of patients with their ethnicity coded on practice computers (88.1%) in this study is unique in a primary care setting. We combined Indians, Pakistanis and Bangladeshis into a single ethnic category of "south Asians" and black African and Caribbeans into a combined "black" group, due to insufficient numbers in subgroups. This may have masked differences in CHD management and outcomes in what are known to be culturally and epidemiologically heterogeneous groups. 32, 33 We examined changes in quality using a broad range of indicators; some of which were incentivised under the family practitioner contract (measurement of total cholesterol, prescribing of aspirin and beta blockers) and others which were not (measurement of BMI, prescribing of statins). Use of routine clinical data means that there may have been some variability in the completeness and accuracy of the information collected. 34 We were also unable to adjust for certain patient factors, such as duration of CHD and presence or severity of complications, which may have been confounders in the relationship between ethnicity and CHD management. Finally, given the major differences between the UK and US health care systems, the findings may not all be transferable to the US. For example, the UK's National Health Service provides universal coverage with access to primary care services free at the point of use. This means that patients from ethnic minority groups in the UK, who are often from lower socio-economic groups, do not face financial barriers in accessing primary healthcare services.
Policy Implications
The introduction of pay for performance incentives in UK primary care has been deemed a major success, with most practices reaching many of the higher Quality and Outcome Framework targets. However, there has been little assessment of the impact of the new contract on known disparities in access to health care [35] [36] [37] and health outcomes, which is a key requirement of all new government policies in the UK. 38 This is largely due to the absence of patient level data in the national reporting system for the contract. Our findings suggest that pay for performance incentives in UK primary care coincided with marked improvements in CHD management and intermediate clinical outcomes, which increased equity across ethnic groups. Moreover, we found that a pay for performance programme improved chronic disease management across a range of quality indicators (both incentivised and non-incentivised), which is consistent with other studies. 31 Whilst the management of CHD remains suboptimal in many patients, improvements in the quality of care seen since the new contract are impressive.
Conclusions
The introduction of a major pay for performance scheme in UK primary care was associated with marked improvements in the management of coronary heart disease. Most patients, including those from ethnic minority groups and living in areas of low socio-economic status, appear to have benefited from the scheme. Whether these improvements in process measures and intermediate outcome measures will translate into improved clinical outcomes and a further reduction in health care disparities remains to be evaluated. Healthcare planners in other countries may wish to consider the introduction of similar pay for performance schemes for their own primary care physicians.
